The DOI matches its Crossref record; 982 of the 982 references it cites were found in a registry or an index.
Drug-induced liver injury
Open accessAbstract
Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that occurs either as a predictable event when an individual is exposed to toxic doses of some compounds or as an unpredictable event with many drugs in common use. Drugs can be harmful to the liver in susceptible individuals owing to genetic and environmental risk factors. These risk factors modify hepatic metabolism and excretion of the DILI-causative agent leading to cellular stress, cell death, activation of an adaptive immune response and a failure to adapt, with progression to overt liver injury. Idiosyncratic DILI is a relative rare hepatic disorder but can be severe and, in some cases, fatal, presenting with a variety of phenotypes, which mimic other hepatic diseases. The diagnosis of DILI relies on the exclusion of other aetiologies of liver disease as specific biomarkers are still lacking. Clinical scales such as CIOMS/RUCAM can support the diagnostic process but need refinement. A number of clinical variables, validated in prospective cohorts, can be used to predict a more severe DILI outcome. Although no pharmacological therapy has been adequately tested in randomized clinical trials, corticosteroids can be useful, particularly in the emergent form of DILI related to immune-checkpoint inhibitors in patients with cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [1]
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
Cited work 10.1128/aac.04976-14 · retracted 2015-12-28 · notice 10.1128/aac.04976-14 · this paper published 2019-08-22
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Francis, B. et al. Temporary removal: reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. J. Hepatol. https://doi.org/10.1016/j.jhep.2018.04.024 (2018).”
Cited work 10.1016/j.jhep.2018.04.024 · retracted 2018-05-03 · notice 10.1016/j.jhep.2018.04.024 · this paper published 2019-08-22
Citations
Cites
2 retracted
Francis, B., Clarke, J. I., Walker, L. E., Brillant, N., Jorgensen, A., Park, B. K., Pirmohamed, M., & Antoine, D. J. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.024 · Cited by 4
RetractedAhrens, J. H., & Sastic, C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04976-14 · Cited by 3
Retracted(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,673
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., & Freeman, B. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1620 · Cited by 7,029
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Esterbauer, H., Schaur, R. J., & Zollner, H. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90192-6 · Cited by 6,672
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K. J., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,027
Research works printed but not linked: 3
- Institute of Medicine. Exploring the Biological Contributions to Human Health: Does Sex Matter? (National Academies Press, 2001).
- Sanjuan-Jimenez, R. et al. Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract]. Hepatology 66, 423A (2017).
- Abu-Sbeih, H., Styskel, B., Blechazz, B., Chalasani, N. & Miller, E. Clinically significant hepatotoxicity due to immune checkpoint inhibitors is rare but leads to treatment discontinuations in high proportion. Hepatology 68, 25A (2018).
Cited by
Sorted by citations
Items 101–200 of 922
Niu, H., Ma, J., Medina‐Caliz, I., Robles‐Diaz, M., Bonilla‐Toyos, E., Ghabril, M., Lucena, M. I., Alvarez‐Alvarez, I., & Andrade, R. J. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17373 · Cited by 37
Self-citationThe molecular pathogenesis of triptolide-induced hepatotoxicity
Hu, Y., Wu, Q., Wang, Y., Zhang, H., Liu, X., Zhou, H., & Yang, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.979307 · Cited by 38
Shi, M., Zhang, J., Li, M., Zhao, Y., Guo, Y., Xu, J., Liu, R., Li, Z., Ren, D., & Liu, P. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00815 · Cited by 38
Hepatotoxicity Induced by Azole Antifungal Agents: A Review Study
Rakhshan, A., Rahmati-Kamel, B., Saffaei, A., & Ardakani, M. T. (2023) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-130336 · Cited by 37
Suzuki, A., & MinjunChen (2024) · Liver International · doi:10.1111/liv.16146 · Cited by 37
Self-citationUmbaugh, D. S., & Jaeschke, H. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1857238 · Cited by 37
Xiao, R., Lv, T., Tu, X., Li, P., Wang, T., Dong, H., Tu, P., & Ai, X. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27931 · Cited by 37
Triptolide induces hepatotoxicity by promoting ferroptosis through Nrf2 degradation
Guo, L., Yang, Y., Ma, J., Xiao, M., Cao, R., Xi, Y., Li, T., Huang, T., & Yan, M. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09930-0 · Cited by 36
Underlying mechanisms and treatment of acetaminophen‑induced liver injury (Review)
Li, R., Wu, H., Xu, Y., Xu, X., Xu, Y., Huang, H., Lv, X., Liao, C., Ye, J., & Li, H. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13471 · Cited by 35
Latham, B. D., Geffert, R. M., & Jackson, K. D. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001430 · Cited by 34
Wang, J., Qiao, W., Xu, L., Zhao, H., Zhang, H., Dong, A., & Yang, X. H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02071k · Cited by 34
Drug-induced liver injury and COVID-19: A review for clinical practice
Ortiz, G. X., Lenhart, G., Becker, M. W., Schwambach, K. H., Tovo, C. V., & Blatt, C. R. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.1143 · Cited by 34
Li, J., Lu, Q., Peng, M., Liao, J., Zhang, B., Yang, D., Huang, P., Yang, Y., Zhao, Q., Han, B., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.116069 · Cited by 34
Chu, M.-T., Chang, W., Pao, S.-C., & Chung, W. (2023) · Biomedicines · doi:10.3390/biomedicines11010177 · Cited by 34
Asparagine protects pericentral hepatocytes during acute liver injury
Sun, Y., Demagny, H., Faure, A., Pontanari, F., Jalil, A., Bresciani, N., Yıldız, E., Korbelius, M., Perino, A., & Schoonjans, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163508 · Cited by 34
Genetic risk factors in the development of idiosyncratic drug-induced liver injury
Stephens, C., Lucena, M. I., & Andrade, R. J. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1854726 · Cited by 32
Self-citationModeling drug-induced liver injury: current status and future prospects
Zeo-Sánchez, D. E. D., Segovia‐Zafra, A., Matilla‐Cabello, G., Pinazo-Bandera, J. M., Andrade, R. J., Lucena, M. I., & Paz, M. V. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2122810 · Cited by 33
Self-citationMitochondrial stress activates YAP/TAZ through RhoA oxidation to promote liver injury
Kwon, A., Lee, N. Y., Yu, J.-H., Choi, M. G., Park, J., & Koo, J. H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06448-5 · Cited by 32
PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches
Wang, J., Bwayi, M. N., Gee, R. R. F., & Chen, T. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1779701 · Cited by 32
Weersink, R. A., Alvarez‐Alvarez, I., Medina‐Cáliz, I., Sanabria‐Cabrera, J., Robles‐Díaz, M., Ortega‐Alonso, A., García‐Cortés, M., Bonilla, E., Niu, H., Soriano, G., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2108 · Cited by 29
Self-citationPrevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study
Yu, Z., Zhao, Y., Jin, J., Zhu, J., Yu, L., & Han, G. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.024 · Cited by 32
Ai, G., Wu, X., Dou, Y., Huang, R., Zhong, L., Liu, Y., Xian, Y., Lin, Z., Li, Y., Su, Z., et al. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113215 · Cited by 32
Gong, J.-Y., Ren, H., Chen, H., Xing, K., Xiao, C., & Luo, J. (2022) · Pharmaceuticals · doi:10.3390/ph15091130 · Cited by 32
Chen, R., Li, W., Li, R., Ai, S., Zhu, H., & Lin, W. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.107845 · Cited by 32
Hu, M., & Chikina, M. D. (2024) · Genome biology · doi:10.1186/s13059-024-03292-w · Cited by 31
Khan, M. Z. I., Ren, J.-N., Cao, C., Ye, H.-Y.-X., Wang, H., Guo, Y.-M., Yang, J., & Chen, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1441587 · Cited by 31
Arginine Metabolism Reprogramming in Perfluorooctanoic Acid (PFOA)-Induced Liver Injury
Gao, J., Li, T., Guo, W., Yan, M., Liu, J., Yao, X., Lv, M., Ding, Y., Qin, H., Wang, M., et al. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.4c07971 · Cited by 31
Beachler, D. C., de Luise, C., Jamal‐Allial, A., Yin, R., Taylor, D. H., Suzuki, A., Lewis, J. H., Freston, J. W., & Lanes, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-07790-z · Cited by 31
Self-citationXu, M., Ren, C., Zhou, Y., Heger, Z., Liang, X., Adam, V., & Li, N. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.008 · Cited by 31
Xi, Y., Chi, Z., Tao, X., Zhai, X., Zhao, Z., Ren, J., Yang, S., & Dong, D. (2023) · Environmental Toxicology · doi:10.1002/tox.23755 · Cited by 31
Efferocytosis in liver disease
Shi, H., Moore, M. P., Wang, X., & Tabas, I. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2023.100960 · Cited by 30
Hepatic Bile Acid Transporters and Drug-induced Hepatotoxicity
Saran, C., & Brouwer, K. L. R. (2023) · Toxicologic Pathology · doi:10.1177/01926233231212255 · Cited by 30
Luteolin attenuates CCl4-induced hepatic injury by inhibiting ferroptosis via SLC7A11
Han, Z., Batudeligen, Chen, H., Narisu, Anda, Xu, Y., & Xue, L. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04486-2 · Cited by 30
Organic afterglow luminescence for disease diagnosis and treatment
Zhao, L., & Miao, Q. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00343-0 · Cited by 30
Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment
Xiong, Y., & Huang, J. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00489-0 · Cited by 30
The Regulatory Roles of Polysaccharides and Ferroptosis-Related Phytochemicals in Liver Diseases
Ren, Y., Li, S., Song, Z., Luo, Q., Zhang, Y., & Wang, H. (2022) · Nutrients · doi:10.3390/nu14112303 · Cited by 30
Involvement of endoplasmic reticulum stress in rifampicin-induced liver injury
Hou, W., Nsengimana, B., Yan, C., Nashan, B., & Han, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1022809 · Cited by 30
Thomas, S. T., Wierenga, K. A., Pestka, J. J., & Olive, A. J. (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2200011 · Cited by 29
Drug-induced cholestatic liver diseases
Bjornsson, E. S., & Devarbhavi, H. C. (2024) · Hepatology · doi:10.1097/hep.0000000000001052 · Cited by 29
Self-citationEnvironmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns
Beier, J. I., & Arteel, G. E. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.005 · Cited by 29
Engineering NIR-II luminescent lanthanide nanoprobes for imaging brain diseases in vivo
Du, Y., Ni, S., Ma, Q., Song, X., & Yang, H. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215401 · Cited by 29
Biagioli, M., Marchianò, S., di Giorgio, C., Roselli, R., Bordoni, M., Bellini, R., Fiorillo, B., Sepe, V., Catalanotti, B., Cassiano, C., et al. (2023) · Hepatology · doi:10.1002/hep.32787 · Cited by 28
Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury
Tao, W., Fan, Q., & Wei, J. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46020078 · Cited by 29
Microfluidic human physiomimetic liver model as a screening platform for drug induced liver injury
Dey, S., Bhat, A., Janani, G., Shandilya, V., Gupta, R., & Mandal, B. B. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122627 · Cited by 29
Chen, P., Zou, F., & Liu, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549526 · Cited by 28
Alnasser, S. M. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04264-y · Cited by 28
New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides
Walles, M., Brown, A. P., Zimmerlin, A. G., & End, P. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00131 · Cited by 28
Yan, X., Lin, W., Liu, H., Pu, W., Li, J., Wu, P., Ding, J., Luo, G., & Zhang, J. (2021) · Small · doi:10.1002/smll.202100045 · Cited by 28
19F Barcoding Enables Multiplex Detection of Biomarkers Associated with Organ Injury and Cancer
Luo, X., Kang, B., Chi, X., Xiong, H., Chen, D., Fan, Y., Li, L., Chen, L., Li, A., Gao, J., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202211189 · Cited by 29
State-of-the-art advancements in Liver-on-a-chip (LOC): Integrated biosensors for LOC
Liu, M., Xiang, Y., Yang, Y., Long, X., Xiao, Z., Nan, Y., Jiang, Y., Qiu, Y., Huang, Q., & Ai, K. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114758 · Cited by 28
MacNair, L., Kulpa, J., Hill, M. L., Eglit, G. M. L., Mosesova, I., Bonn‐Miller, M. O., & Peters, E. N. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0345 · Cited by 28
Artificial Intelligence in Liver Diseases: Recent Advances
Lu, F., Meng, Y., Song, X., Li, X., Liu, Z., Gu, C., Zheng, X., Yi, J., Cai, W., Pinyopornpanish, K., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02781-5 · Cited by 28
Management of Pharmacologic Adverse Effects in Advanced Liver Disease
García‐Cortés, M., & García-García, A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01150-w · Cited by 27
Qian, Y., Zhao, J., Wu, H., & Kong, X. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03886-0 · Cited by 28
Wang, Y., Wang, Y., Liu, Y., Cao, J., Yang, M., Wang, Y., Khan, A., Zhao, T., & Cheng, G. (2022) · Food & Function · doi:10.1039/d2fo00507g · Cited by 27
Frtús, A., Smolková, B., Uzhytchak, M., Lunová, M., Jirsa, M., Henry, S. J. W., Dejneka, A., Stephanopoulos, N., & Lunov, O. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.04.046 · Cited by 27
MicroRNAs: Small molecules with big impacts in liver injury
Halim, A. S. A., Rudayni, H. A., Chaudhary, A. A., & Ali, M. A. M. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30908 · Cited by 27
Ouyang, S., Zhu, J., Cao, Q., Liu, J., Zhang, Z., Zhang, Y., Wu, J., Sun, S., Fu, J., Chen, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202305715 · Cited by 27
Protective effects of naringin on valproic acid-induced hepatotoxicity in rats
Koroglu, O. F., Günata, M., Vardı, N., Yıldız, A., Ateş, B., Çolak, C., Tanrıverdi, L. H., & Parlakpınar, H. (2021) · Tissue and Cell · doi:10.1016/j.tice.2021.101526 · Cited by 27
Wu, Y., Liu, Z., Wu, L., Chen, M., & Tong, W. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.729834 · Cited by 26
A combined “eat me/don’t eat me” strategy based on exosome for acute liver injury treatment
Du, W., Chen, C., Liu, Y., Quan, H., Xu, M., Liu, J., Song, P., Fang, Z., Yue, Z. H., Xu, H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102033 · Cited by 26
Tang, J., Gu, J., Chu, N., Chen, Y., Wang, Y., Xue, D., Xie, Q., Li, L., Mei, Z., Wang, X., et al. (2022) · Liver International · doi:10.1111/liv.15290 · Cited by 25
Zhang, Y., Liu, L., Wang, T., Mao, C., Shan, P., Lau, C. S., Li, Z., Guo, W., & Wang, W. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301394 · Cited by 26
Kainat, K., Ansari, M. I., Bano, N., Jagdale, P. R., Ayanur, A., Kumar, M., & Sharma, P. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122164 · Cited by 26
DILIsym: Quantitative systems toxicology impacting drug development
Watkins, P. B. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.06.003 · Cited by 26
Self-citationCell Death in Liver Disease and Liver Surgery
Stoess, C., Choi, Y., Onyuru, J., Friess, H., Hoffman, H. M., Hartmann, D., & Feldstein, A. E. (2024) · Biomedicines · doi:10.3390/biomedicines12030559 · Cited by 26
Drug-induced liver injury and prospect of cytokine based therapy; A focus on IL-2 based therapies
Kumar, N., Surani, S., Udeani, G., Mathew, S., John, S. R., Sajan, S., & Mishra, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119544 · Cited by 25
Supervised chemical graph mining improves drug-induced liver injury prediction
Lim, S., Kim, Y., Gu, J., Lee, S., Shin, W., & Kim, S. (2022) · iScience · doi:10.1016/j.isci.2022.105677 · Cited by 25
ONOO--triggered fluorescence H2S donor for mitigating drug-induced liver injury
Liu, J., Zhao, M., Zhao, F., Song, X., & Ye, Y. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.133131 · Cited by 25
Zhang, H., Yang, Y., Xie, F., Lan, Y., Lin, L., Song, Z., Gao, L., Huang, Y., & Xiao, P. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116573 · Cited by 25
Bessone, F., Hernandez, N., Medina-Caliz, I., García-Cortés, M., Schinoni, M. I., Mendizabal, M., Chiodi, D., Nunes, V., Ridruejo, E., Pazos, X., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.030 · Cited by 24
Self-citationMitochondrial dysfunction in drug-induced hepatic steatosis: Recent findings and current concept
Borgne‐Sanchez, A., & Fromenty, B. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102529 · Cited by 24
Flores-Peña, R., Monroy-Ramírez, H. C., Caloca-Camarena, F., Arceo-Orozco, S., Salto-Sevilla, J. A., Galicia‐Moreno, M., & Armendáriz‐Borunda, J. (2025) · Antioxidants · doi:10.3390/antiox14080979 · Cited by 24
Predicting Drug-Induced Liver Injury Using Machine Learning on a Diverse Set of Predictors
Adeluwa, T., McGregor, B. A., Guo, K., & Hur, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648805 · Cited by 24
Zhao, L., Yu, Y., Li, L., Wang, J., Wang, J., Su, S., Ding, J., Zhang, Y., Wang, A., & Zhou, K. (2022) · Toxicon · doi:10.1016/j.toxicon.2022.06.018 · Cited by 24
Wang, C., Zhao, S., Xu, Y., Sun, W., Feng, Y., Liang, D., & Guan, Y. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s381667 · Cited by 24
Applications of In Silico Models to Predict Drug-Induced Liver Injury
Lin, J., Li, M., Mak, W. Y., Shi, Y., Zhu, X., Tang, Z., He, Q., & Xiang, X. (2022) · Toxics · doi:10.3390/toxics10120788 · Cited by 24
Chen, D., Lü, Z., Zhao, Y., Xia, L., Liu, C., Zuo, S., Jin, M., Jia, H., Li, S., Zhang, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202306066 · Cited by 24
Segovia‐Zafra, A., Paz, M. V., Serras, A. S., Matilla‐Cabello, G., Bodoque-García, A., Zeo-Sánchez, D. E. D., Niu, H., Álvarez‐Álvarez, I., Sanz‐Villanueva, L., Godec, S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.026 · Cited by 24
Self-citationFu, Z., Duan, Y., Pei, H., Zou, Y., Tang, M., Chen, Y. X., Yang, T., Ma, Z., Yan, W., Su, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01341 · Cited by 24
Machine Learning Models to Predict Inhibition of the Bile Salt Export Pump
McLoughlin, K., Jeong, C. G., Sweitzer, T. D., Minnich, A., Tse, M. J., Bennion, B. J., Allen, J., Calad-Thomson, S., Rush, T. S., & Brase, J. M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00950 · Cited by 24
Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives
Ezhilarasan, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173832 · Cited by 24
Niu, H., Atallah, E., Álvarez‐Álvarez, I., Medina‐Cáliz, I., Aithal, G. P., Arıkan, Ç., Andrade, R. J., & Lucena, M. I. (2022) · Drug Safety · doi:10.1007/s40264-022-01224-w · Cited by 24
Self-citationZheng, H., Peng, W., Liu, M., Li, M., Li, W., Xing, J., Shi, P., Wang, Q., Zhang, S., & Yang, L. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06168 · Cited by 23
Sarma, A. A., Christenson, S. A., Zha, B. S., Pisco, A. O., Neyton, L. P. A., Mick, E., Sinha, P., Wilson, J. G., Moazed, F., Leligdowicz, A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202407-1454oc · Cited by 23
Hepatoprotective effects of carvedilol and crocin against leflunomide-induced liver injury
Sokar, S. S., Alkabbani, M. A., Akool, E., & Abu-Risha, S. E.-S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109297 · Cited by 23
Cueto‐Sánchez, A., Niu, H., Álvarez‐Álvarez, I., López‐Longarela, B., Del Campo‐Herrera, E., Ortega‐Alonso, A., García‐Cortés, M., Pinazo‐Bandera, J., Sanabria‐Cabrera, J., Díaz‐Mochón, J. J., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15724 · Cited by 24
Self-citationLi, C., Niu, M., Liu, Y., Tang, J., Wei, C., Qian, G., Zhang, M., Shi, Y., Lin, J., Li, X., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00810 · Cited by 23
Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies
Mikolajewicz, N., Khan, S., Trifoi, M. D., Skakdoub, A., Ignatchenko, V., Mansouri, S., Zuccato, J., Zacharia, B. E., Glantz, M., Zadeh, G. M., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac161 · Cited by 22
Therapeutic potential of sulforaphane in liver diseases: a review
Liang, Y., & Yan, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1256029 · Cited by 22
Sesquiterpenoids from the sunflower family as potential anti-inflammatory candidates: a review
Chen, C., Feng, Z., Petrović, J. D., Sokóvić, M., Ye, Y., & Lin, L. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0026 · Cited by 22
Dietary modulation of gut microbiota affects susceptibility to drug-induced liver injury
Pan, H., Song, D., Wang, Z., Yang, X., Luo, P., Li, W., Li, Y., Gong, M., & Zhang, C. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2439534 · Cited by 22
Oda, S., Uchida, Y., Aleo, M. D., Koza‐Taylor, P., Matsui, Y., Hizue, M., Marroquin, L. D., Whritenour, J., Uchida, E., & Yokoi, T. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02882-4 · Cited by 22
Serious liver injury induced by Nimesulide: an international collaborative study
Bessone, F., Hernández, N., Mendizábal, M., Ridruejo, E., Gualano, G., Fassio, E., Peralta, M., Fainboim, H. A., Anders, M., Tanno, H., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03000-8 · Cited by 22
Self-citationMoreira, J. L. D. S., Barbosa, S. M. B., & Júnior, J. G. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101752 · Cited by 22
Drug-Induced Liver Injury—Pharmacological Spectrum Among Children
Maris, B. R., Grama, A., & Pop, T. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052006 · Cited by 21
Advancing hepatotoxicity assessment: current advances and future directions
Kim, Y., Kim, Y., & Kim, Y. (2025) · Toxicological Research · doi:10.1007/s43188-025-00289-w · Cited by 22
Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update
Barnhill, M. S., Steinberg, J. M., Jennings, J. J., & Lewis, J. H. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-00781-3 · Cited by 21
Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5
Wang, J., Buchman, C. D., Seetharaman, J., Miller, D. J., Huber, A. D., Wu, J., Chai, S. C., Garcia-Maldonado, E., Wright, W. C., Chenge, J., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07066 · Cited by 21
Novel Clinical Biomarkers for Drug-Induced Liver Injury
Chen, Y., Guan, S., Guan, Y., Tang, S., Zhou, Y., Wang, X., Bi, H., & Huang, M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000732 · Cited by 21
Metadata
- Authors
- Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., & Aithal, G. P.
- Affiliations
- Indiana University School of Medicine (US)
- Duke University (US)
- Novartis (Switzerland) (CH)
- University of North Carolina at Chapel Hill (US)
- St.John's Medical College Hospital (IN)
- University of Zurich (CH)
- Spanish Clinical Research Network (ES)
- Nottingham University Hospitals NHS Trust (GB)
- Corresponding author
- Lucena, M. Isabel
- ORCID
- Venue
- Nature Reviews Disease Primers
- Published
- 2019-08-22
- Volume
- 5
- Issue
- 1
- Pages
- 58-58
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W1565605888
- Cited by
- 924
- References
- 982
- Citations by year
- 2026: 152 · 2025: 197 · 2024: 161 · 2023: 127 · 2022: 145 · 2021: 97 · 2020: 38
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.zora.uzh.ch
- Licence
- Locations
- Nature Reviews Disease Primers (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug reactions, xenobiotic toxicity, genetic susceptibility, hepatic metabolism, immune response, corticosteroids, immune checkpoint inhibitors, hepatotoxicity
- MeSH terms
- Biopsy, Humans, Risk Factors, Biomarkers, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
